FDA Inspection 1123773 — Kaysersberg Pharmaceuticals SAS

Kaysersberg Pharmaceuticals SAS — FEI 3002806288

The FDA completed an inspection of Kaysersberg Pharmaceuticals SAS on Feb 1, 2019 in Kaysersberg. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 1, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Kaysersberg (France)

Additional Details

Mutual Recognition Agreement (MRA)